Ariel Investments LLC grew its position in Envista Holdings Co. (NYSE:NVST - Free Report) by 6.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,059,624 shares of the company's stock after buying an additional 699,625 shares during the quarter. Envista accounts for 2.5% of Ariel Investments LLC's holdings, making the stock its 8th largest holding. Ariel Investments LLC owned approximately 7.01% of Envista worth $232,630,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista in the fourth quarter valued at approximately $53,000. Lecap Asset Management Ltd. acquired a new position in shares of Envista during the fourth quarter worth about $281,000. Hantz Financial Services Inc. lifted its holdings in shares of Envista by 146.6% in the 4th quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company's stock valued at $2,131,000 after buying an additional 65,679 shares during the period. Norges Bank purchased a new position in shares of Envista in the 4th quarter valued at about $38,052,000. Finally, Natixis Advisors LLC increased its holdings in Envista by 1.8% in the fourth quarter. Natixis Advisors LLC now owns 106,652 shares of the company's stock valued at $2,057,000 after buying an additional 1,845 shares in the last quarter.
Envista Stock Up 5.8 %
Envista stock traded up $0.97 during mid-day trading on Thursday, hitting $17.81. 1,136,984 shares of the company's stock were exchanged, compared to its average volume of 2,522,998. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. The stock has a market cap of $3.02 billion, a P/E ratio of -2.74, a P/E/G ratio of 1.27 and a beta of 0.97. The stock has a 50 day moving average of $16.52 and a two-hundred day moving average of $19.01. Envista Holdings Co. has a 1-year low of $14.22 and a 1-year high of $23.00.
Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.04. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. The firm had revenue of $616.90 million during the quarter, compared to the consensus estimate of $608.17 million. During the same period in the prior year, the firm earned $0.26 EPS. The business's revenue was down 1.1% on a year-over-year basis. As a group, analysts anticipate that Envista Holdings Co. will post 1 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the company. Wells Fargo & Company set a $19.00 target price on Envista in a research note on Saturday, March 8th. UBS Group cut their price target on shares of Envista from $21.00 to $18.00 and set a "neutral" rating on the stock in a report on Monday. Piper Sandler lowered their target price on Envista from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Needham & Company LLC reissued a "hold" rating on shares of Envista in a research report on Thursday, March 6th. Finally, Morgan Stanley set a $16.00 price target on shares of Envista in a research report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $20.08.
Check Out Our Latest Stock Analysis on Envista
Envista Profile
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
